Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08), Zacks reports.
Bicara Therapeutics Stock Down 3.0 %
Shares of NASDAQ BCAX traded down $0.39 during midday trading on Tuesday, hitting $12.65. The company had a trading volume of 159,823 shares, compared to its average volume of 465,337. The business has a 50-day simple moving average of $13.06 and a two-hundred day simple moving average of $17.80. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09.
Wall Street Analyst Weigh In
A number of brokerages recently commented on BCAX. Wedbush restated an "outperform" rating and set a $31.00 target price on shares of Bicara Therapeutics in a report on Thursday, March 27th. HC Wainwright raised their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, January 27th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics has a consensus rating of "Buy" and an average price target of $36.50.
Check Out Our Latest Report on Bicara Therapeutics
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
